These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33315170)

  • 1. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
    Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
    Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 4. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
    Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
    Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union.
    Takizawa A; Kamita M; Kondoh Y; Bando M; Kuwana M; Inoue Y
    Curr Med Res Opin; 2021 Feb; 37(2):327-339. PubMed ID: 33287583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
    Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
    Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
    J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype.
    Inoue Y; Kaner RJ; Guiot J; Maher TM; Tomassetti S; Moiseev S; Kuwana M; Brown KK
    Chest; 2020 Aug; 158(2):646-659. PubMed ID: 32268131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.